CN1256985C - Method for manufacturing chitosan capillary and application thereof - Google Patents
Method for manufacturing chitosan capillary and application thereof Download PDFInfo
- Publication number
- CN1256985C CN1256985C CN 200410036143 CN200410036143A CN1256985C CN 1256985 C CN1256985 C CN 1256985C CN 200410036143 CN200410036143 CN 200410036143 CN 200410036143 A CN200410036143 A CN 200410036143A CN 1256985 C CN1256985 C CN 1256985C
- Authority
- CN
- China
- Prior art keywords
- chitosan
- solution
- controlled release
- capillary pipe
- capillary tube
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Abstract
The present invention relates to a manufacturing method for a chitosan capillary pipe, which is characterized in that the chitosan powder of which the molecular weight is from 500 thousand to 1 million is added into a 0.5% to 3% acetic acid water solution. After the gas in the solution is escaped, a stainless steel straight wire is immersed into the liquid, and then the steel wire of which the surface is uniformly attached with the chitosan is immersed into a NaOH solution; the stainless steel straight wire is taken out after formation; the formed capillary pipe is placed into distilled water to be soaked for 100 to 200 minutes until the pH value of the distilled water is from 6 to 8; after being taken out from a soaking solution and dried, the capillary pipe is stored in alcohol to be used. The chitosan capillary pipe is used as a slow controlled release administration device for treating human diseases. The present invention has the advantages of simple manufacturing method, convenient operation and easy control. The biological property of good compatibility with the human organism of the chitosan which is a marine organism material is used. The degrading speed is slow, and the disadvantages on the aspects of unsatisfactory treating effect, hemolysis, heat source reaction and permeability of the slow controlled release administration are overcome.
Description
Technical field
The present invention relates to a kind of chitosan method for manufacturing capillary pipe and application.
Background technology
At present, in the slow controlled release drug administration treatment of disease, used medicine has gentamycin, amycin etc., during medication and gelatin, albumin or polyesters synthetic macromolecule material make the purpose that microcapsule reaches slow controlled release drug administration, its shortcoming is a complex manufacturing technology, and the degradation speed of these materials is fast, and slow controlled release drug administration therapeutic effect is undesirable, and all has shortcoming aspect haemolysis, heat source response, the permeability.
Summary of the invention
The purpose of this invention is to provide a kind of chitosan method for manufacturing capillary pipe, and this product is delayed the controlled release drug administration device as the treatment human diseases, can overcome the above-mentioned shortcoming of prior art.
A kind of chitosan method for manufacturing capillary pipe, it is characterized in that adding molecular weight in the aqueous acetic acid of 0.5-3% is the chitosan powder of 50-100 ten thousand, form the chitosan solution of 1-3%, in this solution behind the gas evolution, immerse this liquid with the rustless steel raw silk rings,. the steel wire that makes the surface evenly hang up chitosan then immerses in the NaOH solution, soaked 100-240 minute, after the typing rustless steel raw silk rings is taken out, the capillary tube that forms is put into distilled water soaks 100-200 minute to distilled water PH6-8, with capillary tube in soak, takes out carry out drying afterwards in ethanol preservation stand-by.
Above-mentioned chitosan capillary tube is as the slow controlled release drug administration device of treatment human diseases.
Advantage of the present invention is that manufacture method is simple, and is easy to operate, is easy to control.Utilized marine organism material chitosan and the good biological nature of the tissue compatibility, and degradation speed is slow, has overcome also that slow controlled release drug administration therapeutic effect is undesirable, the shortcoming of haemolysis, heat source response, permeability aspect.
The specific embodiment
When making chitosan capillary tube of the present invention, to 1% (concentration expressed in percentage by weight, the adding molecular weight is 600,000 chitosan powder in the aqueous acetic acid down together), form 3% chitosan solution, rotary viscosity 4000mpa.s, treat in the liquid to immerse this liquid with the rustless steel raw silk rings behind the gas evolution, make this raw silk rings surface evenly hang up chitosan.Then it is taken out in the NaOH aqueous solution that immerses 1N, soak typing in 100 minutes.After the typing rustless steel raw silk rings is taken out, the capillary tube that forms is put into distilled water be dipped to PH7, capillary tube is taken out in soak carry out cold drying and put into 65% medical alcohol to its water content to 20% and preserve.
Capillary tube of the present invention delays the application examples of controlled release drug administration device in the conduct of treatment disease:
1. bone tumor postoperative local recurrence is clinical comparatively stubborn problem, need this moment local application to eliminate remaining tumor cell, amycin is injected the chitosan capillary tube seal the preparation administration, and carry out the vitro inhibition OS-116 bone tumor test of extracorporeal releasing test and leachate thereof.The result confirms, should make amycin be slowly stable release by slow controlled release drug administration device, the suppression ratio of the OS-116 of its 1st, 10,20,30,40,50 and 60 day leachate be respectively: 58.51%, 43.32%, 36.52%, 27.11%, 24.32%, 22.13%, 21.61%.Based on this above-mentioned slow controlled release drug administration device that amycin is housed is implanted rabbit tibia upper end and carry out vivo releasing test, and compare with the rabbit of quiet notes same dose amycin.The result shows with should slow controlled release drug administration device administration, can make amycin part in osseous tissue keep higher concentration and reach about 10 weeks, and this maximum concentration 26 times of bone content when being quiet notes same dose, plasma peak concentration only is 1/11 of a quiet notes plasma peaks.This result has confirmed this slow good slow control-release function of controlled release drug administration device, should make the once local consumption of amycin can satisfy big, the medication requirement long, that haemoconcentration is low, general reaction is little of holding time of local chemotherapy dosage well by slow controlled release drug administration device above about 10 times of quiet notes ampoule.Residual cavity adopts 6 times of slow controlled release drug administrations of the chitosan capillary tube to conventional vein amycin consumption after the clinical 4 routine giant cell tumor of bone curettage.Amycin content is respectively in 1,2 and 5 days blood plasma of postoperative: 141.06 ± 26.98ng/ml, 53.19 ± 12ng/ml and 4.36 ± 3.12ng/ml, 7 days, 30 days, 180 days hepatic and renal function of postoperative is all normal.Followed up a case by regular visits to 7 months-20 months, no local recurrence, general reaction and X line do not have the recurrence performance.Conclusion: it is safe and effective that the slow controlled release drug administration device of chitosan capillary tube amycin is used for after the giant cell tumor of bone curettage.
The chitosan capillary tube as gentamycin medicine sustained and controlled release doser to results in treatment of chronic osteomyelitis.
With 20 rabbit is experimental subject, adopt external, vivo releasing test, estimate the effect of chitosan capillary tube as gentamycin medicine sustained and controlled release doser, clinical employing chitosan capillary tube is implanted affected part 10 examples as gentamycin medicine sustained and controlled release doser with operation, and with postoperative wound healing state, clinical manifestation and X line performance evaluation curative effect.Extracorporeal releasing test shows that first day burst size is 926.7ug, descends thereafter, and with stable release of 40ug reduced levels every day, reaches 28 days; Vivo releasing test shows that the blood drug level peak value is 0.95ug/ml, occurs at 24h; Postoperative blood urea nitrogen (BUN) and creatinine (Cr) value do not have to be increased; Gentamicin concentration is still more than the common pathogenic malicious MIC of osteomyelitis in postoperative the 8th all chitosan capillary tube gentamycin medicine sustained and controlled release doser surrounding bone tissues.Clinical 10 routine patients all obtain and follow up a case by regular visits to, and follow up a case by regular visits to average 25.8 months time 6-36 month.Initial stage healing rate 88.7% does not have recurrence. and chitosan capillary tube gentamycin medicine sustained and controlled release doser has slow control-release function in the better body, for the treatment infection of bone better effects is arranged clinically.
Claims (2)
1, a kind of chitosan method for manufacturing capillary pipe, it is characterized in that adding molecular weight in the aqueous acetic acid of 0.5-3% is the chitosan powder of 50-100 ten thousand, form the chitosan solution of 1-3%, in this solution behind the gas evolution, immerse this liquid with the rustless steel raw silk rings, the steel wire that makes the surface evenly hang up chitosan then immerses in the NaOH solution, soaked 100-240 minute, after the typing rustless steel raw silk rings is taken out, the capillary tube that forms is put into distilled water soaks 100-200 minute to distilled water PH6-8, with capillary tube in soak, takes out carry out drying afterwards in ethanol preservation stand-by.
2, the application of chitosan capillary tube in slow controlled release drug administration device of making by the method for claim 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410036143 CN1256985C (en) | 2004-10-25 | 2004-10-25 | Method for manufacturing chitosan capillary and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410036143 CN1256985C (en) | 2004-10-25 | 2004-10-25 | Method for manufacturing chitosan capillary and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1634590A CN1634590A (en) | 2005-07-06 |
| CN1256985C true CN1256985C (en) | 2006-05-24 |
Family
ID=34845775
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410036143 Expired - Fee Related CN1256985C (en) | 2004-10-25 | 2004-10-25 | Method for manufacturing chitosan capillary and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1256985C (en) |
-
2004
- 2004-10-25 CN CN 200410036143 patent/CN1256985C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1634590A (en) | 2005-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2001247579B2 (en) | Matrices containing nitric oxide donors and reducing agents and their use | |
| US20030039697A1 (en) | Matrices containing nitric oxide donors and reducing agents and their use | |
| AU2020101591A4 (en) | A thermosensitive gel, preparation method and application thereof | |
| JP2015510818A (en) | Silk reservoir for drug delivery | |
| US20090130017A1 (en) | Targeted short-lived drug delivery | |
| EA015793B1 (en) | Method of treating acromegaly and related symptoms therewith and an implant used therefor | |
| JPH07505378A (en) | Wound treatment treatment for fibrotic disorders | |
| CN103690490A (en) | System and method for generating nitric oxide based on microencapsulated chemical reactants | |
| JP2003501152A (en) | Anti-infectious device and method of manufacturing the same | |
| CN105326535A (en) | Medical anastomosis nail and preparation method thereof | |
| CN103990185A (en) | Carrageenan and gelatin microsphere embolization agent and preparation method thereof | |
| KR20140133724A (en) | Parenteral Drug Delivery System based on low Molecular Polysaccharides | |
| CN111000794B (en) | Bletilla polysaccharide/bioglass temperature-sensitive gel and preparation method and application thereof | |
| CN1256985C (en) | Method for manufacturing chitosan capillary and application thereof | |
| CN106562953B (en) | Application, drug and process for preparing medicine of the hydroxyl radical carthamin yellow carthamus A in the drug of preparation treatment diabetic foot ulcer | |
| JP2010503665A (en) | How to make insulin in the form of an oral preparation | |
| CN108354922A (en) | A kind of pharmaceutical preparation and preparation method thereof for treating diabetes chronic ulcer | |
| CN208492943U (en) | Band coating screw thread catheter | |
| CN104586484B (en) | A kind of backbone implantation unit and preparation method thereof | |
| CN105832730A (en) | Cloxacillin sodium and clotrimazole composition and application thereof to biological medicines | |
| Kamalpuria et al. | The Latest Methods and Technologies of Pulsatile Drug Delivery System: A Review. | |
| Tan et al. | Degradable microneedle patch loaded with doxycycline hydrochloride and vascular endothelial growth factors for promoting diabetic wound healing | |
| CN105213326A (en) | A kind of preparation method of clindamycin phosphate for injection lyophilized powder | |
| JP6153838B2 (en) | Vascular permeability inhibitor | |
| CN102441171A (en) | Local temperature-sensitive antibacterial drug sustained-release agent and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |